Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Investing Activities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash from Investing Activities for 13 consecutive years, with -$100.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 476.16% to -$100.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$90.2 million, a 94.17% decrease, with the full-year FY2024 number at $12.3 million, up 137.57% from a year prior.
  • Cash from Investing Activities was -$100.2 million for Q3 2025 at Theravance Biopharma, down from -$36.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $113.7 million in Q1 2021 to a low of -$100.2 million in Q3 2025.
  • A 5-year average of $2.8 million and a median of $7.5 million in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: soared 139.56% in 2024, then plummeted 1096.24% in 2025.
  • Theravance Biopharma's Cash from Investing Activities stood at $113.7 million in 2021, then crashed by 65.56% to $39.2 million in 2022, then tumbled by 209.92% to -$43.0 million in 2023, then skyrocketed by 136.44% to $15.7 million in 2024, then plummeted by 739.08% to -$100.2 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Cash from Investing Activities are -$100.2 million (Q3 2025), -$36.3 million (Q2 2025), and $30.6 million (Q1 2025).